14
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study sub-analysis
Saturday, March 28, 2015: 2:33 PM
International Ballroom (Hilton Chicago)
U. A. Matulonis1, R. T. Penson2, S. M. Domchek3, B. Kaufman4, M. W. Audeh5, S. B. Kaye6, L. R. Molife6, H. Mann7, J. Robertson7 and R. L. Coleman8
1Dana-Farber Cancer Institute, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA, 3Basser Research Center and Abramson Cancer Center, Philadelphia, PA, 4Sheba Medical Center, Tel Hashomer, Israel, 5Samuel Oschin Cancer Institute, Los Angeles, CA, 6The Royal Marsden Hopital, London, United Kingdom, 7AstraZeneca, Macclesfield, United Kingdom, 8The University of Texas MD Anderson Cancer Center, Houston, TX
